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Summary
 
Heat shock protein (HSP) preparations derived from cancer cells and virus-infected cells have
been shown previously to elicit cancer-specific or virus-specific immunity. The immunogenic-
ity of HSP preparations has been attributed to peptides associated with the HSPs. The studies
reported here demonstrate that immunogenic HSP–peptide complexes can also be reconsti-
tuted in vitro. The studies show that (
 
a
 
) complexes of hsp70 or gp96 HSP molecules with a va-
riety of synthetic peptides can be generated in vitro; (
 
b
 
) the binding of HSPs with peptides is
specific in that a number of other proteins tested do not bind synthetic peptides under the con-
ditions in which gp96 molecules do; (
 
c
 
) HSP–peptide complexes reconstituted in vitro are im-
munologically active, as tested by their ability to elicit antitumor immunity and specific CD8
 
1
 
cytolytic T lymphocyte response; and (
 
d
 
) synthetic peptides reconstituted in vitro with gp96
are capable of being taken up and re-presented by macrophage in the same manner as gp96–
peptides complexes generated in vivo. These observations demonstrate that HSPs are CD8
 
1
 
 T
cell response–eliciting adjuvants.
 
I
 
mmunization with heat shock protein (HSP)
 
1
 
 prepara-
tions isolated from cancer cells or virus-infected cells has
been reported to elicit protective antitumor or antiviral cel-
lular immune response (1–8). This paradigm has also been
substantiated in other antigenic systems, such that gp96
HSP preparations isolated from a cell expressing a trans-
fected cytosolic protein can immunize and elicit specific
CTLs against that antigen (9). Similarly, gp96 preparations
isolated from cells expressing a given set of minor H anti-
gens can be used to immunize and elicit CTL response
against the minor antigens expressed by the cells that were
the source of the immunizing gp96 preparation (9). HSPs
are not polymorphic molecules and do not differ in their
primary structure among normal tissues and cancers, or
among normal and virus-infected cells. In this light, the re-
markably general immunizing ability of HSP preparations
has been explained on the basis of the suggestion that the
HSP molecules are associated with peptides generated in
the cells from which the HSPs are isolated (10). Peptides
associated with gp96 and hsp70 have since been demon-
strated (6, 11) and it has been shown that dissociation of the
HSP-bound peptides leads to abrogation of immunogenicity
of the HSP preparation (6). Confirmation of these results
has also been obtained in a viral system, as a recent study has
demonstrated that gp96 preparations isolated from vesicular
stomatitis virus (VSV)-infected cells contain VSV-derived
peptides (12). It has been suggested that cytosolic and en-
doplasmic reticular HSPs chaperone antigenic peptides
during antigen processing and presentation by MHC class I
molecules (13). The mechanism by which such noncova-
lent HSP–peptide complexes elicit protective cellular immune
responses has recently been elucidated (14, 15).
The HSP–peptide interaction is at the center of this
newly emerging immunological paradigm. In this report,
we demonstrate that HSP–peptide complexes can also be gen-
erated in vitro and that the biological activity of these
complexes is comparable to that of HSP–peptide complexes
generated in vivo. Further, the HSP–peptide complexes re-
constituted in vitro elicit immunity by a mechanism appar-
ently identical to that implicated in the immunogenicity of
the complexes generated in vivo.
 
Materials and Methods
 
Mice and Cell Lines.
 
Female C57BL/6 (6–8 wk old) were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). EL4 cells
are a thymoma of C57BL/6 origin. N1 is a clone of EL4 trans-
 
1
 
Abbreviations used in this paper:
 
 HSP, heat shock protein; NP, nucleocap-
soid protein; VSV, vesicular stomatitis virus.
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fected with the nucleocapsid gene of VSV (16). VSV-specific
CTLs were derived from mice that were immunized with irradi-
ated (7,500 rads) N1 cells. 7 d after immunization, splenocytes (8 
 
3
 
10
 
6
 
) from immune mice were cultured with irradiated N1 cells (5 
 
3
 
10
 
4
 
) in 24-well plates. CTLs were restimulated every 7 d. Pristane-
induced peritoneal exudate cells were used for macrophage enriched
population.
 
Purification of HSPs.
 
gp96 was purified from C57BL/6 liver
cells, as described (2). In brief, 15 livers were homogenized in 40
ml of hypotonic buffer (30 mM NaHCO
 
3
 
, 0.1 mM phenylmeth-
ylsulfonyl fluoride, pH 7.1) by a tissue tearor, and a 100,000 
 
g
 
 su-
pernatant was obtained. The supernatant was fractionated by 50–
70% ammonium sulfate precipitation, applied to a concanavalin
A–agarose column, and glycoproteins were eluted by 10% 
 
a
 
-meth-
ylmannoside. The eluate was applied to a DEAE–agarose column,
equilibrated with 0.3 M NaCl, and was eluted with 0.7 M NaCl.
Hsp70 was purified as described by Peng et al. (17).
 
HSP–Peptide Binding.
 
gp96 and 
 
125
 
I-labeled peptides (synthe-
sized by Bio-Synthesis, Inc., Lewisville, TX), were mixed in the
quantities indicated, and incubated for 10 min at the indicated
temperatures in a binding buffer (20 mM Hepes, pH 7.2, 20 mM
NaCl, and 2 mM MgCl
 
2
 
). The samples were then incubated for
30 min at room temperature. Alternatively, gp96 and peptides
were coincubated in sodium phosphate buffer at 25 or 50
 
8
 
C, as
indicated, for 10 min at various salt concentrations, followed by
incubation at room temperature for 30 min. In the case of hsp70,
high temperatures and high salt concentrations were unnecessary;
hsp70 and peptides were coincubated at 37
 
8
 
C in sodium phos-
phate buffer containing 1 mM ADP and 1 mM MgCl
 
2
 
. Free pep-
tide was removed completely using a microcon 50 (Amicon, Inc.,
Beverly, MA). The removal of free peptides was monitored by
electrophoretic analysis of the labeling mixture, followed by
quantitative autoradiography; if peptides were not removed, they
were visible on the dye front. Samples were also analyzed by sil-
ver staining or immunoblotting with anti-gp96 antibody (anti-
GRP94, SPA-850, clone 9G10; NeoMarkers, Fremont, CA) or
anti-hsp70 antibody (clone BRM22 from NeoMarkers). Peptide
quantification was determined by densitometry using the Quan-
tity 1 (version 2.2) program with the PDI Discovery series system
(Sun Microsystems).
 
Tumor Rejection Assay.
 
Mice were injected subcutaneously
with 10 
 
m
 
g or 25 
 
m
 
g reconstituted HSP–peptide complexes, or
gp96 alone, peptide alone (75 nM), or buffer twice at weekly in-
tervals. Mice were challenged intraperitoneally with 5,000 live
N1 tumor cells 7 d after the second immunization.
 
CTL Assay.
 
Spleen cells (8 
 
3
 
 10
 
6
 
/well) from immunized
mice (day 96) were cultured in mixed lymphocyte tumor culture
with 7,500 rads irradiated antigen-positive cells or cognate pep-
tide-pulsed cell (5 
 
3
 
 10
 
4
 
/well) in 24-well plates. After 5 d, mixed
lymphocyte tumor cultures were tested for cytotoxicity in a chro-
mium release assay.
 
TNF-
 
a
 
 Bioassay.
 
Macrophages (1.5 
 
3
 
 10
 
4
 
) and VSV-specific
CTLs (5 
 
3
 
 10
 
4
 
) were cultured with serially diluted reconstituted
VSV–gp96 complexes for 24 h at 37
 
8
 
C. Supernatants were col-
lected and assayed for TNF-
 
a
 
 production in a cytotoxicity assay
as described (15).
 
Results
 
Exchange of Peptides Naturally Bound to HSPs with Exoge-
nous Peptides.
 
The ability of gp96 molecules to bind pep-
tides in vitro was analyzed using an electrophoretic assay.
The rationale for the use of this assay was as follows: it had
been demonstrated earlier that gp96 preparations obtained
from preparative sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE) could still be used to elicit
limited but significant tumor-specific immunity (2). This
observation seen in the context of subsequent studies,
which suggested that gp96 preparations are immunogenic
because of association of gp96 with antigenic peptides (11,
12), indicated that gp96–peptide interaction would be ex-
pected to be stable under conditions of SDS-PAGE.
The peptide A (KRQIYTDLEMNRLGK) derived from
G protein of the VSV was used for the initial studies. This
peptide has been shown previously to bind hsp70 mole-
cules in vitro (18). Apparently homogeneous, unlabeled
gp96 preparations were incubated at 37
 
8
 
C with iodinated
peptide A as described in Materials and Methods. The sam-
ple was analyzed by SDS-PAGE with or without additional
heating of the sample in SDS-PAGE sample buffer, fol-
lowed by autoradiography. The expectation from such an
experiment is that SDS-resistant binding of unlabeled gp96
to labeled peptide will result in a labeled 96-kD band.
However, no binding of gp96 to peptide A is detected un-
der these conditions. The possibility was considered that
incubation of gp96 with exogenous peptides at higher tem-
peratures might permit dissociation of naturally bound pep-
tides followed by reannealing of a proportion of exoge-
nously added radiolabeled peptides at lower temperatures.
Iodinated preparations of peptide A were incubated with
unlabeled gp96 at 4, 25, 37, 60, or 90
 
8
 
C for 10 min and al-
lowed to cool to room temperature for an additional 30
min. The samples were analyzed by SDS-PAGE without
further heating and the gels were stained for proteins and
autoradiographed. It was observed (Fig. 1) that exoge-
nously added labeled peptide A could associate with gp96
in a temperature-dependent manner with optimal binding
at 60
 
8
 
C. Little binding is detected at 4, 25, 37, or 90
 
8
 
C. Al-
though the intensity of label in the gp96 band varies at dif-
ferent temperatures and at different peptide concentrations
(Fig. 1, 
 
A
 
 and 
 
B
 
), the quantity of gp96 as detected by silver
staining is constant in all lanes (Fig. 1 
 
C
 
). It was also ob-
served that the gp96–peptide binding can be dissociated, if
the complexes are heated in a boiling water bath (data not
shown).
The exchange of exogenous and native-bound peptides
could also be achieved by incubation of gp96 with exoge-
nous peptides at high salt concentrations. Gp96 prepara-
tions were incubated at 25 or 50
 
8
 
C with radio-iodinated
peptide VSV19 (extended on both termini of K
 
b
 
-binding
VSV nucleocapsid protein (NP)-derived octamer VSV8)
for 10 min in sodium phosphate buffer containing 200
mM, 300 mM, 500 mM, 700 mM, 800 mM, 1 M, 2 M, or
3 M NaCl, followed by 30 min at room temperature. The
samples were desalted and analyzed by SDS-PAGE, fol-
lowed by staining as well as autoradiography. It was ob-
served (Fig. 2) that significant quantities of labeled peptides
formed an SDS-resistant association with gp96 after incu-
bation at 2 M or higher NaCl concentration, but not at
lower concentrations. In presence of high salt, the extent of 
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association of gp96 with peptides was comparable at the
low and high temperatures, whereas at low salt concentra-
tions, gp96–peptide interaction was detected only at the
higher temperature. The quantity of gp96 in each lane, as
judged by Coomassie blue staining and scanning, was iden-
tical.
Reconstitution of peptides with hsp70 molecules was
observed to require neither a heating and cooling cycle,
nor exposure to high salt concentrations. Incubation of ap-
parently homogeneous preparations of hsp70 with radiola-
beled peptide A in sodium phosphate buffer containing 1
mM ADP and 1 mM MgCl
 
2
 
 at 37
 
8
 
C was found to be suffi-
cient to generate SDS-stable hsp70–peptide complexes as
judged by autoradiography (see Fig. 5 
 
A
 
).
Binding of gp96 or hsp70 to peptides is not restricted to
peptide A and can also be demonstrated for an array of
other peptides, such as peptide B, LSSLFRPKRRPIYKS
(derived from VSV G protein; reference 18); peptide C,
SLSDLRGYVYQGLKSGNVS (derived from VSV nucle-
oprotein; reference 18); peptide D, IASNENMETMESS-
TLE (derived from nucleoprotein of influenza virus strain
A/PR/8/34); and peptide E, SFIRGTKVSPRGKLST
(derived from nucleoprotein of influenza virus A/NY/60/
68) (data not shown). To evaluate the specificity of binding
of peptides to gp96, unlabeled peptides A, B, C, D, and E
were tested for their ability to compete with labeled pep-
tide A in the gp96–peptide A binding assay. gp96, 25 pmol
radiolabeled peptide A, and 0.1 or 10 nmol unlabeled pep-
tides A, B, C, D, or E were coincubated at 50
 
8
 
C, followed
by a 30-min incubation at room temperature. It was ob-
served that all peptides could compete with peptide A in
binding to gp96, although with different efficiencies (Fig. 3
 
A
 
). As expected, higher quantities (10 nmol) of competing
unlabeled peptides were more effective in displacing la-
beled peptide A than the lower quantities in the case of all
peptides except peptide E, in which case the competition
was already saturating at the lower quantity.
The specificity of binding of HSPs with the exogenous
peptide was demonstrated in the following additional ways,
as shown here for gp96, but also observed for hsp70. (
 
a
 
) In-
clusion of BSA or OVA in gp96–peptide A binding reac-
tion had no influence on gp96–peptide A binding (Fig. 3
 
B
 
); (
 
b
 
) a number of proteins, i.e., 
 
a
 
–2 macroglobulin, 
 
b
 
-galac-
tosidase, fructose-6-phosphate kinase, OVA, pyruvate kinase,
fumarase, and triosephosphate isomerase were tested for their
ability to bind peptide A and were observed to not bind it
(Fig. 3 
 
C
 
); and (
 
c
 
) it was demonstrated that only the intact
gp96 and not any of its various degradation products could
bind peptide A (Fig. 3 
 
C
 
).
The quantity of peptide bound to the HSPs in vitro was
determined. The specific radioactivity of the peptides (cpm/
mol of peptide) was measured; using this number, the
number of moles of peptides bound to a given quantity of
gp96 were determined by measuring the cpm in the HSP
band after autoradiography, by cutting out the band and
counting it in a 
 
g
 
 counter. This calculation revealed that
under the conditions tested, and assuming a stoichiometry
of one peptide per HSP molecule, 
 
z
 
1% of HSP molecules
were loaded with the exogenous peptide. The assumption
of a 1:1 stoichiometry between HSP and peptides was
made on the basis of the recent demonstration of a single
peptide-binding pocket in a bacterial hsp70 molecule (19).
 
Immunogenicity of HSP–peptide Complexes Reconstituted In
Vitro.
 
gp96–peptide complexes and hsp70–peptide com-
Figure 1. gp96 binds to peptides in vitro. gp96 (10 pmol) was incu-
bated with increasing concentrations of radioiodinated peptide A (25, 75,
and 125 pmol) for 10 min at different temperatures in 20 ml reaction
buffer, followed by 30 min at room temperature. The reaction was termi-
nated by mixing with sample buffer (0.1% SDS, 20% glycerol, and 5%
bromophenol blue) and analyzed by SDS-PAGE. (A) Autoradiogram af-
ter 48-h exposure. (B) Densitometric quantification of results in A. An al-
iquot of each reaction was analyzed in parallel by SDS-PAGE and silver
staining (C).
Figure 2. Exchange of exogenous and native-bound peptides at high
salt concentrations. gp96 (40 pM) and iodinated synthetic peptide (2 nM,
NH2–Ser–Leu–Ser–Asp–Leu–Arg–Gly–Tyr–Val–Tyr–Gln–Gly–Leu–Lys–
Ser–Gly–Asn–Val–Ser–COOH) were mixed in phosphate buffer in 20 ml
reaction volume and incubated at 25 or 508C for 10 min. After centrifu-
gation, the mixtures were incubated at 258C for another 30 min. Samples
were analyzed by SDS-PAGE and staining, followed by autoradiography
of the stained gel (24-h exposure). 
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plexes generated in vitro were tested in a variety of models
for their ability to elicit CTLs and tumor immunity. For
generation of CTLs, seven model peptides, which bind to
different MHC class I alleles, were tested. These derive
from OVA (K
 
b
 
), SV40 T antigen (D
 
b
 
), NP antigen of in-
fluenza virus (D
 
b
 
 and K
 
b
 
), NP antigen of VSV (K
 
b
 
), and
 
b
 
-galactosidase (L
 
d
 
). The peptides were complexed with
gp96, hsp70, or both and mice of the appropriate haplotype
(b or d) were immunized twice at weekly intervals, with
the peptides alone (10 
 
m
 
g peptide in PBS), the uncom-
plexed HSPs alone (20–50 
 
m
 
g HSP in PBS), or the HSP–
peptide complexes (20–50 
 
m
 
g HSP complexed with 
 
z
 
2 ng
peptide, determined as described in the previous section).
Spleen cells from the immunized mice were put in culture
and were stimulated with the cognate peptide and tested
for cytotoxic activity on target cells pulsed or unpulsed
with relevant peptides. It was observed (Fig. 4) that T cells
obtained from mice immunized with peptides alone or
with gp96 or hsp70 alone showed no cytotoxic activity,
whereas T cells obtained from mice immunized with HSP–
peptide complexes showed significant and consistent pep-
tide-specific CTL activity. The precise MHC class I–bind-
ing peptides were used in these studies. To test whether
larger peptides than the exact epitopes could be complexed
with HSPs and used to immunize successfully, a 19-mer
precursor of K
 
b
 
-binding VSV8 (VSV19) was complexed
with hsp70 and gp96 and the complexes used to immunize.
The HSP–VSV19 complexes were found to be as effective
at eliciting antigen-specific CTL response as the HSP–
VSV8 complexes were (Fig. 4).
A number of parameters of the adjuvant activity of gp96
and hsp70 were tested. The possibility that complexing of
HSPs with peptides is unnecessary and HSP–peptide mix-
tures (instead of complexes) may be equally immunogenic
was tested. It was observed that, similar to the results of im-
munization with HSPs or peptides alone, mixtures of HSPs
and peptides were consistently nonimmunogenic. Simi-
larly, when mice were immunized with HSPs on one flank
and peptides on the other, no CTL response was detected
(data not shown).
The possibility that immunization with peptides mixed
or complexed with any large molecule, particularly other
carrier molecules, might also elicit a potent and specific
CTL response was investigated. The VSV9 peptide (Tyr–
VSV8) was mixed with a traditional carrier protein, mouse
serum albumin, under conditions that facilitate binding
with gp96 and hsp70. The complexed material was ana-
lyzed by SDS-PAGE, and mouse serum albumin, like gp96
and hsp70, was found to form an SDS-resistant complex
with the peptide (Fig. 5 
 
A
 
). Mice were immunized with
mouse serum albumin–VSV9 complex, and were tested for
CTL response as described previously. No CTL response
was detected (Fig. 5 
 
B
 
). On the other hand, Gp96–VSV9
and hsp70–VSV9 complexes elicited significant specific
CTL responses (Fig. 5 
 
B
 
).
These observations demonstrate that the HSPs gp96 and
hsp70 possess an adjuvant activity effective for eliciting a
CD8
 
1
 
 T cell response. The efficacy of HSP–peptide vacci-
nation in eliciting tumor rejection was tested in an artificial
model, because the identity of peptides that can elicit rejec-
tion of natural tumors is yet unknown. Tumor rejection
studies were carried out using the N1 tumor, which has
been derived by transfection of the EL4 lymphoma of the
C57BL/6 mouse with the gene encoding the NP of the
VSV. Therefore, VSV–NP is a model tumor rejection anti-
gen for this tumor (16). (In the past, we have actively re-
frained from using tumor models in which foreign genes
have been transfected into tumors, as they reveal little
about tumor immunity. However, this model is used in the
present study to measure an antigen-specific T cell response
in vivo.) Thus, gp96 molecules obtained from normal livers
of C57BL/6 mice were complexed with the VSV8 known
to bind K
 
b
 
. C57BL/6 mice were immunized with such re-
constituted complexes, or with VSV8 alone, or with liver
gp96 alone, and were challenged with N1 cells. Survival of
mice was monitored (Fig. 6). It was observed that there was
no difference in the survival kinetics of unimmunized mice
and mice immunized with liver gp96 or the VSV8 alone:
all mice died within 30–50 d of tumor challenge. In con-
trast, 8 of 10 mice immunized with gp96–VSV8 complexes
Figure 3. Specificity of peptide binding by gp96. (A) Unlabeled pep-
tides A, B, C, D, and E (0.1 and 10 nM) were used to compete with la-
beled peptide A (25 pmol) for the binding to gp96 (10 pmol). The se-
quences of these peptides are described in the text. The binding assay
described in the legend to Fig. 1 was used, except that binding was carried
out at 508C. (B) Albumin and ovalbumin do not compete with gp96 for
binding to peptide A. gp96 (10 pmol) was incubated with 25-pmol radio-
labeled peptide A and analyzed as in the legend to Fig. 1. Albumin and
ovalbumin (10 pmol each) were included in the binding assay. The auto-
radiogram and the silver stained gel are shown. (C) A partially degraded
preparation of gp96 and a mixture of six purified proteins (i.e., a–2 mac-
roglobulin,  b-galactosidase, fructose-6-phosphokinase, pyruvate kinase,
fumarase, and triosephosphate isomerase) were tested for binding to iodi-
nated peptide A. Only the intact gp96 molecule is able to form a stable
complex with radioactive peptide A. None of the other six proteins tested
are able to bind peptide A.1319 Blachere et al.
reconstituted in vitro, survived beyond 100 d after tumor
challenge. Spleens of the immunized mice were also tested
for antigen-specific CTL response to the VSV8 epitope. It
was observed that mice immunized with the gp96–VSV8
complex generated effective antigen-specific, CD81 CTL
response, whereas mice immunized with gp96 alone, or the
VSV8 alone, did not (data not shown). These results indi-
cate that the peptides complexed with gp96 in vitro elicit
tumor immunity in a manner consistent with the gp96–
peptide complexes generated in vivo. Similar antitumor ac-
tivity has been shown for hsp70–peptide complexes (data
not shown).
Re-presentation of Peptides Reconstituted with gp96 In Vitro,
by MHC Class I Molecules of Macrophages. The mechanism
whereby immunization with gp96–peptide complexes gen-
erated in vivo leads to a protective CTL response has been
elucidated (15). It has been shown that gp96–peptide com-
plexes are taken up by macrophages and the chaperoned
peptides are re-presented by the MHC class I molecules of
the macrophage through a novel pathway. The immuno-
logical activity of the gp96–peptide complexes generated in
vitro was tested in this assay. gp96 preparations were recon-
stituted with the VSV8 peptide at different temperatures
and the resulting complexes were used to pulse pristane-
induced macrophages of C57BL/6 mice in vitro. The pulsed
macrophages were tested for their ability to stimulate anti-
VSV CTLs, as measured by the secretion of TNF-a by the
CTLs (Fig. 7). It was observed that the macrophage pulsed
with complexes reconstituted at 608C were effective in this
re-presentation assay, whereas those reconstituted at 37, 80,
or 988C were not. As we have shown previously (15), the
quantity of VSV8 complexed with gp96 in these experi-
ments is z2 log scales lower than that necessary for direct
charging of the empty surface MHC class I molecules by
the VSV8 peptides. Data in Fig. 7 show that the gp96–pep-
tide complexes reconstituted in vitro appear to be re-pre-
sented by the antigen-presenting cells in the same manner
as shown previously (15) for the natural HSP–peptide com-
plexes.
Discussion
The studies described here indicate that HSP–peptide com-
plexes can be reconstituted in vitro and that, by all parame-
Figure 4. Hsp–peptide complexes reconstituted in vitro prime mice for CD81 T cell response. Mice were immunized with HSPs alone (20–50 mg),
peptides alone (10 mg), or HSP–peptide complexes (20–50 mg), as indicated. 1 wk after the last immunization, spleens were removed and stimulated with
the cognate peptide or with cells transfected with the gene encoding the relevant antigen. The lymphocyte cultures were tested for their ability to lyse
cells transfected with the antigen of interest (closed circle) and the nontransfected parental line (open circle). For the top panel, HSPs alone were tested for
their immunizing ability in each antigenic system and were found to be consistently negative. The CTL responses were tested in many but not all systems
and where tested, were found to be MHC class I and CD8 restricted.1320 Heat Shock Proteins as CTL-eliciting Adjuvants of Mammalian Origin
ters tested, such complexes show immunological activity
similar to the HSP–peptide complexes generated in vivo.
The results also show significant differences between gp96
and hsp70 with respect to the conditions in vitro, under
which they bind peptides. These differences presumably re-
flect the fact that although hsp70–ATP interaction plays a
crucial role in hsp70–peptide interaction in vivo, the iden-
tity of the corresponding ligand for gp96 is presently un-
known. In contrast with the situation with hsp70, gp96–ATP
interaction does not strip gp96 of its associated peptides
(data not shown), even though gp96, like hsp70, is an
ATP-binding protein and is an ATPase (11). Exposure to
high temperature and high salt apparently causes the gp96
molecule to assume an open conformation, which permits
dissociation from and association with exogenous peptides.
The identity of the ligands that catalyze this process in vivo
would be of interest in this regard.
The observations reported here have several implications.
First, they support the hypothesis that immunogenicity of
tumor-derived gp96 preparations results from a physical as-
sociation of gp96 with antigenic peptides. The HSP–pep-
tide complex elicits immunity under conditions in which
the HSP molecules alone, or the peptides alone, do not.
Second, these observations show that one does not have to
rely on HSP–peptide complexes generated in vivo to elicit
immunity; instead, such complexes can be generated repro-
ducibly in vitro, provided the identity of the immunogenic
peptides is known. A variety of peptides of different lengths,
compositions, and hydrophobicity can bind the HSPs, sug-
gesting that the nature of an epitope is not a limiting factor
in its suitability as a vaccine in the form of a HSP–peptide
complex. The ability of the gp96 to bind peptides in vitro
has also been independently demonstrated recently (20).
The quantity of peptide that is required to be conjugated to
the HSPs is extremely small and 1–2 ng of peptides com-
plexed to the HSPs elicit potent cellular immune response.
At first sight, this quantity may appear to be unrealistically
small; however, when it is considered that the peptides
chaperoned by the HSPs are targeted specifically to the
professional antigen-presenting cells (15, 21), 1–2 ng or z6
Figure 5. Chaperoning of
peptides by HSPs is required for
generation of an effective CD81
T cell response. gp96, hsp70, or
mouse serum albumin (MSA)
were complexed with radiola-
beled VSV9 and analyzed by (A)
SDS-PAGE followed by Coo-
massie blue staining and autora-
diography. In addition, mice
were immunized (B) with pep-
tides complexed or simply mixed
with each of the proteins. Sple-
nocytes of these mice were
tested for induction of CD81 T
lymphocytes, as described in leg-
end to Fig. 4. N1 (closed circle)
and EL4 (open circle) were used as
targets.1321 Blachere et al.
3 1011 molecules of specific peptide targeted to the rele-
vant antigen-presenting cells are actually a large number, as
argued in more detail elsewhere (22). This observation has
significant implications for vaccination against infectious
diseases in which the protective epitopes are known, and
for any cancers, such as those of viral etiology, that may
share antigenic epitopes.
Essentially, these results show that HSPs are adjuvants.
This adjuvanticity has a number of unique characteristics:
in contrast with other nonlive adjuvants, the adjuvanticity
of HSPs generates MHC class I–restricted T cell responses.
No serological antipeptide response has ever been detected
among the tens of immunized mice tested (data not shown).
The quantitative requirements of antigens administered
with HSPs are log scales lower than corresponding require-
ments for other adjuvants. Finally, HSPs are the first adju-
vants of mammalian origin. We have suggested previously
that the immunogenicity of HSP–peptide complexes may
reflect the role in vivo of such complexes in priming of cel-
lular immune responses (23). In this view, the observed ad-
juvanticity of HSPs is simply a reflection of the natural role
of HSPs in vivo.
The structural basis of the ability of gp96 molecules to
bind a variety of peptides is presently unclear and requires
further study. Obviously, there are certain rules for the
HSP–peptide interaction as seen in the observation that
peptides differ in their ability to compete with a given pep-
tide for binding to gp96 (Fig. 3). However, the studies car-
ried out here are not of a broad enough scope to permit
elucidation of these rules. Broadly speaking, HSP–peptide
interaction is reminiscent of MHC–peptide interaction,
which was equally mysterious as to its structural basis until
the rules of interaction were identified (24). The MHC and
the HSPs share a number of crucial properties, such as the
ability to bind peptides, a ubiquitous tissue distribution,
high degree of phylogenetic conservation, inducibility of
the respective genes by IFN-g (25) and, finally, the ability
to prime CTL responses against the peptides chaperoned by
them. These considerations led us in the past (26) to sug-
gest a phylogenetic relationship between the MHC and the
HSPs, and a number of recent observations (19, 27–28)
have not been inconsistent with that suggestion. The asso-
ciation of peptides with HSPs of the cytosol (hsp70 and
hsp90) and the endoplasmic reticulum (gp96) had also led
us to suggest that HSPs constitute a relay line of molecules
that chaperones the peptides and ultimately delivers them
to the MHC class I molecules (23). Therefore, the HSPs
were suggested to be accessories to antigen presentation by
MHC class I molecules. Our recent results, which show
that peptides precursors to the MHC class I–binding epitopes
are found in specific association with hsp70, hsp90, and
gp96 (Ishii et al., manuscript submitted for publication), are
in accord with our suggestion. The recent demonstration
by Lammert et al. (29) that the HSP gp96 acts as a major
peptide acceptor for peptides transported into the lumen of
the endoplasmic reticulum through transport-associated
protein molecules, also supports the relay-line hypothesis.
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